and when would that be ???
no one has even been interested in partnering with SGYP for plecanatide ?? they couldn't use the PhII data for registration & have to run two large Ph. III studies for CIC the first of which just started Nov 2013 with no timeline to topline results given. The Ph.IIB IBS-C topline results won't be known until sometime later in 2014..."best in class" ? Riddle me this: why wouldn't anyone interested in profits partner with SGYP if they have a "best in class" drug for a huge market opportunity with an unmet medical need, Sparky ???
Not to play devil's advocate but there is a simple answer to that:
SGYP has said MANY times they do not want a partnership. They want to retain 100% ownership. As to the best in class claim... Data would agree. Sorry. Facts are facts.
Im wondering, sparky, do you know the history of both compounds? And WHO actually created it, sparky?